Advanced search
Publication Cover
Expert Review of Vaccines Volume 15, 2016 - Issue 2
Submit an article Journal homepage
1,352
Views
33
CrossRef citations to date
0
Altmetric
Reviews

Understanding respiratory syncytial virus (RSV) vaccine development and aspects of disease pathogenesis

Patricia A. JorqueraDepartment of Infectious Disease, College of Veterinary Medicine, University of Georgia, Athens, GA, GeorgiaORCID Iconhttps://orcid.org/0000-0002-8111-5138
ORCID Icon,
Lydia AndersonDepartment of Infectious Disease, College of Veterinary Medicine, University of Georgia, Athens, GA, Georgia
&
Ralph A. TrippDepartment of Infectious Disease, College of Veterinary Medicine, University of Georgia, Athens, GA, GeorgiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2924-9956
ORCID Icon
Pages 173-187 | Received 09 Sep 2015, Accepted 27 Oct 2015, Published online: 05 Dec 2015

References

  • Harris J, Werling D. Binding and entry of respiratory syncytial virus into host cells and initiation of the innate immune response. Cell Microbiol. 2003;5:671–680.
  • Castilow EM, Meyerholz DK, Varga SM. Il-13 is required for eosinophil entry into the lung during respiratory syncytial virus vaccine-enhanced disease. J Immunol. 2008;180:2376–2384.
  • Oshansky CM, Zhang W, Moore E, et al. The host response and molecular pathogenesis associated with respiratory syncytial virus infection. Future Microbiol. 2009;4:279–297.

•• This review discusses RSV manipulation of the host response to infection and related disease pathogenesis.

  • Polack FP. The changing landscape of respiratory syncytial virus. Vaccine. 2015. pii: S0264-410X(15)01072-5.
  • Krishnamoorthy N, Khare A, Oriss TB, et al. Early infection with respiratory syncytial virus impairs regulatory t cell function and increases susceptibility to allergic asthma. Nat Med. 2012;18:1525–1530.

• It describes the mechanism by which viral infection targets a host-protective mechanism in early life and increases susceptibility to allergic disease.

  • Kiss G, Holl JM, Williams GM, et al. Structural analysis of respiratory syncytial virus reveals the position of m2-1 between the matrix protein and the ribonucleoprotein complex. J Virol. 2014;88:7602–7617.
  • Guvenel AK, Chiu C, Openshaw PJ. Current concepts and progress in rsv vaccine development. Expert Rev Vaccines. 2014;13:333–344.
  • Anderson LJ. Respiratory syncytial virus vaccine development. Semin Immunol. 2013;25:160–171.

•• This review discuss the different RSV vaccine approaches.

  • Graham BS. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev. 2011;239:149–166.
  • Kurt-Jones EA, Popova L, Kwinn L, et al. Pattern recognition receptors tlr4 and cd14 mediate response to respiratory syncytial virus. Nat Immunol. 2000;1:398–401.

• This paper describes the role of TLR4 in RSV infection.

  • Murawski MR, Bowen GN, Cerny AM, et al. Respiratory syncytial virus activates innate immunity through toll-like receptor 2. J Virol. 2009;83:1492–1500.
  • Rallabhandi P, Phillips RL, Boukhvalova MS, et al. Respiratory syncytial virus fusion protein-induced toll-like receptor 4 (tlr4) signaling is inhibited by the tlr4 antagonists rhodobacter sphaeroides lipopolysaccharide and eritoran (e5564) and requires direct interaction with md-2. MBio. 2012;3(4). pii: e00218-12.
  • Lambert SL, Aslam S, Stillman E, et al. A novel respiratory syncytial virus (rsv) f subunit vaccine adjuvanted with gla-se elicits robust protective th1-type humoral and cellular immunity in rodent models. PLoS One. 2015;10:e0119509.
  • Turner TM, Jones LP, Tompkins SM, et al. A novel influenza virus hemagglutinin-respiratory syncytial virus (rsv) fusion protein subunit vaccine against influenza and rsv. J Virol. 2013;87:10792–10804.
  • McLellan JS, Chen M, Leung S, et al. Structure of rsv fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science. 2013;340:1113–1117.
  • McLellan JS, Yang Y, Graham BS, et al. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol. 2011;85:7788–7796.
  • Magro M, Andreu D, Gomez-Puertas P, et al. Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein. J Virol. 2010;84:7970–7982.
  • McLellan JS, Chen M, Joyce MG, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science. 2013;342:592–598.
  • Liang B, Surman S, Amaro-Carambot E, et al. Enhanced neutralizing antibody response induced by respiratory syncytial virus pre-fusion f protein expressed by a vaccine candidate. J Virol. Forthcoming 2015. doi:10.1128/JVI.01373-15.
  • Krarup A, Truan D, Furmanova-Hollenstein P, et al. A highly stable prefusion rsv f vaccine derived from structural analysis of the fusion mechanism. Nat Commun. 2015;6:8143.

• This paper shows that the prefusion form of the RSV F protein can be stanilized and used as vaccine for the induction of neutralizing antibodies.

  • Cheon IS, Shim BS, Park SM, et al. Development of safe and effective rsv vaccine by modified cd4 epitope in g protein core fragment (gcf). PLoS One. 2014;9:e94269.
  • McLellan JS, Ray WC, Peeples ME. Structure and function of respiratory syncytial virus surface glycoproteins. Curr Top Microbiol Immunol. 2013;372:83–104.
  • Tripp RA, Jones LP, Haynes LM, et al. Cx3c chemokine mimicry by respiratory syncytial virus g glycoprotein. Nat Immunol. 2001;2:732–738.

• This paper describes the RSV G protein CX3C chemokine motif.

  • Griese M. Respiratory syncytial virus and pulmonary surfactant. Viral Immunol. 2002;15:357–363.
  • Malhotra R, Ward M, Bright H, et al. Isolation and characterisation of potential respiratory syncytial virus receptor(s) on epithelial cells. Microbes Infect. 2003;5:123–133.
  • Ghildyal R, Hartley C, Varrasso A, et al. Surfactant protein a binds to the fusion glycoprotein of respiratory syncytial virus and neutralizes virion infectivity. J Infect Dis. 1999;180:2009–2013.
  • Jorquera PA, Choi Y, Oakley KE, et al. Nanoparticle vaccines encompassing the respiratory syncytial virus (rsv) g protein cx3c chemokine motif induce robust immunity protecting from challenge and disease. PLoS One. 2013;8:e74905.
  • Schepens B, Schotsaert M, Saelens X. Small hydrophobic protein of respiratory syncytial virus as a novel vaccine antigen. Immunotherapy. 2015;7:203–206.
  • Lee YN, Hwang HS, Kim MC, et al. Recombinant influenza virus carrying the conserved domain of respiratory syncytial virus (rsv) g protein confers protection against rsv without inflammatory disease. Virology. 2015;476:217–225.
  • Gu H, Li T, Han L, et al. Protection conferred by virus-like particle vaccines against respiratory syncytial virus infection in mice by intranasal vaccination. Hum Vaccin Immunother. 2015;11:1057–1064.
  • Gan SW, Ng L, Lin X, et al. Structure and ion channel activity of the human respiratory syncytial virus (hrsv) small hydrophobic protein transmembrane domain. Protein Sci. 2008;17:813–820.
  • Bueno SM, Gonzalez PA, Cautivo KM, et al. Protective t cell immunity against respiratory syncytial virus is efficiently induced by recombinant bcg. Proc Natl Acad Sci U S A. 2008;105:20822–20827.
  • Cautivo KM, Bueno SM, Cortes CM, et al. Efficient lung recruitment of respiratory syncytial virus-specific th1 cells induced by recombinant bacillus calmette-guerin promotes virus clearance and protects from infection. J Immunol. 2010;185:7633–7645.
  • Blodorn K, Hagglund S, Fix J, et al. Vaccine safety and efficacy evaluation of a recombinant bovine respiratory syncytial virus (brsv) with deletion of the sh gene and subunit vaccines based on recombinant human rsv proteins: n-nanorings, p and m2-1, in calves with maternal antibodies. PLoS One. 2014;9:e100392.
  • Pierantoni A, Esposito ML, Ammendola V, et al. Mucosal delivery of a vectored rsv vaccine is safe and elicits protective immunity in rodents and nonhuman primates. Mol Ther Methods Clin Dev. 2015;2:15018.
  • Demirjian A, Levy O. Safety and efficacy of neonatal vaccination. Eur J Immunol. 2009;39:36–46.

•• This review focuses on safety and efficacy of neonatal vaccination and the recent research employing novel approaches to enhance efficacy of neonatal vaccination.

  • Malloy AM, Falsey AR, Ruckwardt TJ. Consequences of immature and senescent immune responses for infection with respiratory syncytial virus. Curr Top Microbiol Immunol. 2013;372:211–231.
  • Schickli JH, Dubovsky F, Tang RS. Challenges in developing a pediatric rsv vaccine. Hum Vaccin. 2009;5:582–591.
  • Oliveira DB, Iwane MK, Prill MM, et al. Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis. J Clin Virol. 2015;65:26–31.
  • Forbes ML, Kumar VR, Yogev R, et al. Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants. Hum Vaccin Immunother. 2014;10:2789–2794.
  • Chi H, Hsu CH, Chang JH, et al. A novel six consecutive monthly doses of palivizumab prophylaxis protocol for the prevention of respiratory syncytial virus infection in high-risk preterm infants in taiwan. PLoS One. 2014;9:e100981.
  • Banerji A, Panzov V, Young M, et al. The real-life effectiveness of palivizumab for reducing hospital admissions for respiratory syncytial virus in infants residing in nunavut. Can Respir J. 2014;21:185–189.
  • Siegrist CA. Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. Vaccine. 2003;21:3406–3412.

•• This review focuses on the mechanisms by which maternal antibodies can inhibit infant immune responses.

  • Siegrist CA, Lambert PH. Maternal immunity and infant responses to immunization: factors influencing infant responses. Dev Biol Stand. 1998;95:133–139.
  • Shinoff JJ, O’Brien KL, Thumar B, et al. Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus. J Infect Dis. 2008;198:1007–1015.
  • Englund JA, Mbawuike IN, Hammill H, et al. Maternal immunization with influenza or tetanus toxoid vaccine for passive antibody protection in young infants. J Infect Dis. 1993;168:647–656.
  • Adedinsewo DA, Noory L, Bednarczyk RA, et al. Impact of maternal characteristics on the effect of maternal influenza vaccination on fetal outcomes. Vaccine. 2013;31:5827–5833.
  • Healy CM, Rench MA, Baker CJ. Importance of timing of maternal combined tetanus, diphtheria, and acellular pertussis (tdap) immunization and protection of young infants. Clin Infect Dis. 2013;56:539–544.
  • Chu HY, Englund JA. Maternal immunization. Clin Infect Dis. 2014;59:560–568.
  • Chu HY, Steinhoff MC, Magaret A, et al. Respiratory syncytial virus transplacental antibody transfer and kinetics in mother-infant pairs in bangladesh. J Infect Dis. 2014;210:1582–1589.
  • Munoz FM. Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy? Curr Opin Infect Dis. 2015;28:221–224.
  • Falsey AR, Hennessey PA, Formica MA, et al. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005;352:1749–1759.
  • Falsey AR, Walsh EE. Respiratory syncytial virus infection in elderly adults. Drugs Aging. 2005;22:577–587.
  • Ponnappan S, Ponnappan U. Aging and immune function: molecular mechanisms to interventions. Antioxid Redox Signal. 2011;14:1551–1585.
  • Falsey AR, Walsh EE, Capellan J, et al. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines–nonadjuvanted vaccine or vaccine adjuvanted with alum–given concomitantly with influenza vaccine to high-risk elderly individuals. J Infect Dis. 2008;198:1317–1326.
  • RSV: Transmission and prevention [Internet]. Center for Disease Control and Prevention; 2014 [cited 2015 Nov 24]. Available from: http://www.cdc.gov/rsv/about/transmission.html
  • Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis. 2008;47:401–409.

• This article reviews different types of immune correlates for vaccine efficacy.

  • Chen RT, Markowitz LE, Albrecht P, et al. Measles antibody: reevaluation of protective titers. J Infect Dis. 1990;162:1036–1042.
  • Permar SR, Klumpp SA, Mansfield KG, et al. Limited contribution of humoral immunity to the clearance of measles viremia in rhesus monkeys. J Infect Dis. 2004;190:998–1005.
  • Permar SR, Klumpp SA, Mansfield KG, et al. Role of cd8(+) lymphocytes in control and clearance of measles virus infection of rhesus monkeys. J Virol. 2003;77:4396–4400.
  • Polack FP, Lee SH, Permar S, et al. Successful DNA immunization against measles: neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles. Nat Med. 2000;6:776–781.
  • Pan CH, Valsamakis A, Colella T, et al. Modulation of disease, t cell responses, and measles virus clearance in monkeys vaccinated with h-encoding alphavirus replicon particles. Proc Natl Acad Sci U S A. 2005;102:11581–11588.
  • Poste G. Bring on the biomarkers. Nature. 2011;469:156–157.
  • Siber GR, Leszcynski J, Pena-Cruz V, et al. Protective activity of a human respiratory syncytial virus immune globulin prepared from donors screened by microneutralization assay. J Infect Dis. 1992;165:456–463.
  • Glenn GM, Smith G, Fries L, et al. Safety and immunogenicity of a sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine. 2013;31:524–532.
  • Walsh EE, Peterson DR, Falsey AR. Risk factors for severe respiratory syncytial virus infection in elderly persons. J Infect Dis. 2004;189:233–238.
  • Caidi H, Harcourt JL, Tripp RA, et al. Combination therapy using monoclonal antibodies against respiratory syncytial virus (rsv) g glycoprotein protects from rsv disease in balb/c mice. PLoS One. 2012;7:e51485.
  • Miao C, Radu GU, Caidi H, et al. Treatment with respiratory syncytial virus g glycoprotein monoclonal antibody or f(ab’)2 components mediates reduced pulmonary inflammation in mice. J Gen Virol. 2009;90:1119–1123.
  • Collarini EJ, Lee FE, Foord O, et al. Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from b cells of infected patients. J Immunol. 2009;183:6338–6345.
  • Choi Y, Mason CS, Jones LP, et al. Antibodies to the central conserved region of respiratory syncytial virus (rsv) g protein block rsv g protein cx3c-cx3cr1 binding and cross-neutralize rsv a and b strains. Viral Immunol. 2012;25:193–203.
  • Zhang W, Choi Y, Haynes LM, et al. Vaccination to induce antibodies blocking the cx3c-cx3cr1 interaction of respiratory syncytial virus g protein reduces pulmonary inflammation and virus replication in mice. J Virol. 2010;84:1148–1157.
  • Boyoglu-Barnum S, Gaston KA, Todd SO, et al. A respiratory syncytial virus (rsv) anti-g protein f(ab’)2 monoclonal antibody suppresses mucous production and breathing effort in rsv ra2-line19f-infected balb/c mice. J Virol. 2013;87:10955–10967.
  • Boyoglu-Barnum S, Todd SO, Chirkova T, et al. An anti-g protein monoclonal antibody treats rsv disease more effectively than an anti-f monoclonal antibody in balb/c mice. Virology. 2015;483:117–125.
  • Haynes LM, Caidi H, Radu GU, et al. Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (rsv) g protein mediates viral clearance and reduces the pathogenesis of rsv infection in balb/c mice. J Infect Dis. 2009;200:439–447.
  • Radu GU, Caidi H, Miao C, et al. Prophylactic treatment with a g glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (rsv)-challenged naive and formalin-inactivated rsv-immunized balb/c mice. J Virol. 2010;84:9632–9636.
  • Geskey JM, Thomas NJ, Brummel GL. Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (rsv). Biologics. 2007;1:33–43.
  • Raghunandan R, Lu H, Zhou B, et al. An insect cell derived respiratory syncytial virus (rsv) f nanoparticle vaccine induces antigenic site ii antibodies and protects against rsv challenge in cotton rats by active and passive immunization. Vaccine. 2014;32:6485–6492.
  • Smith G, Raghunandan R, Wu Y, et al. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats. PLoS One. 2012;7:e50852.
  • Walsh EE, Falsey AR. Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults. J Infect Dis. 2004;190:373–378.
  • Mills JT, Van Kirk JE, Wright PF, et al. Experimental respiratory syncytial virus infection of adults. Possible mechanisms of resistance to infection and illness. J Immunol. 1971;107:123–130.
  • Habibi MS, Jozwik A, Makris S, et al. Impaired antibody-mediated protection and defective iga b-cell memory in experimental infection of adults with respiratory syncytial virus. Am J Respir Crit Care Med. 2015;191:1040–1049.
  • Kim YI, DeVincenzo JP, Jones BG, et al. Respiratory syncytial virus human experimental infection model: provenance, production, and sequence of low-passaged memphis-37 challenge virus. PLoS One. 2014;9:e113100.
  • Cherukuri A, Patton K, Gasser RA, et al. Adults 65 years old and older have reduced numbers of functional memory t cells to respiratory syncytial virus fusion protein. Clinical Vaccine Immunol: CVI. 2013;20:239–247.
  • Lee FE-H, Walsh EE, Falsey AR, et al. The balance between influenza- and rsv-specific cd4 t cells secreting il-10 or ifnγ in young and healthy-elderly subjects. Mech Ageing Dev. 2005;126:1223–1229.
  • Fulton RB, Weiss KA, Pewe LL, et al. Aged mice exhibit a severely diminished cd8 t cell response following respiratory syncytial virus infection. J Virol. 2013;87:12694–12700.
  • Domachowske JB, Rosenberg HF. Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment. Clin Microbiol Rev. 1999;12:298–309.
  • Ha M, Kim VN. Regulation of microrna biogenesis. Nat Rev Mol Cell Biol. 2014;15:509–524.

•• This review focuses on how microRNAs are produced and how they target gene expression.

  • Bartel DP. Micrornas: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–297.
  • Romero-Cordoba SL, Salido-Guadarrama I, Rodriguez-Dorantes M, et al. Mirna biogenesis: biological impact in the development of cancer. Cancer Biol Ther. 2014;15:1444–1455.
  • Inchley CS, Sonerud T, Fjaerli HO, et al. Nasal mucosal microrna expression in children with respiratory syncytial virus infection. BMC Infect Dis. 2015;15:150.
  • Hirakawa S, Kojima T, Obata K, et al. Marked induction of matrix metalloproteinase-10 by respiratory syncytial virus infection in human nasal epithelial cells. J Med Virol. 2013;85:2141–2150.
  • Yeo SJ, Yun YJ, Lyu MA, et al. Respiratory syncytial virus infection induces matrix metalloproteinase-9 expression in epithelial cells. Arch Virol. 2002;147:229–242.
  • Dabo AJ, Cummins N, Eden E, et al. Matrix metalloproteinase 9 exerts antiviral activity against respiratory syncytial virus. PLoS One. 2015;10:e0135970.
  • Bont L, Heijnen CJ, Kavelaars A, et al. Local interferon-gamma levels during respiratory syncytial virus lower respiratory tract infection are associated with disease severity. J Infect Dis. 2001;184:355–358.
  • Brand HK, Ferwerda G, Preijers F, et al. Cd4+ t-cell counts and interleukin-8 and ccl-5 plasma concentrations discriminate disease severity in children with rsv infection. Pediatr Res. 2013;73:187–193.
  • Mella C, Suarez-Arrabal MC, Lopez S, et al. Innate immune dysfunction is associated with enhanced disease severity in infants with severe respiratory syncytial virus bronchiolitis. J Infect Dis. 2013;207:564–573.
  • Brown PM, Schneeberger DL, Piedimonte G. Biomarkers of respiratory syncytial virus (rsv) infection: specific neurotrophin and cytokine levels provide increased accuracy in predicting disease severity. Paediatr Respir Rev. Paediatr Respir Rev. 2015 May 23. pii: S1526-0542(15)00038-X. doi:10.1016/j.prrv.2015.05.005.
  • Khan N, Smith MT. Neurotrophins and neuropathic pain: role in pathobiology. Molecules. 2015;20:10657–10688.
  • Zampieri N, Chao MV. Mechanisms of neurotrophin receptor signalling. Biochem Soc Trans. 2006 Aug;34(Pt 4):607–611.
  • Reichardt LF. Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci. 2006 Sep 29;361(1473):1545–1564.
  • Piedimonte G, Walton C, Samsell L. Vertical transmission of respiratory syncytial virus modulates pre- and postnatal innervation and reactivity of rat airways. PLoS One. 2013;8:e61309.
  • Tortorolo L, Langer A, Polidori G, et al. Neurotrophin overexpression in lower airways of infants with respiratory syncytial virus infection. Am J Respir Crit Care Med. 2005;172:233–237.
  • Matsuse H, Tsuchida T, Fukahori S, et al. Differential airway inflammatory responses in asthma exacerbations induced by respiratory syncytial virus and influenza virus a. Int Arch Allergy Immunol. 2013;161:378–382.
  • Wedde-Beer K, Hu C, Rodriguez MM, et al. Leukotrienes mediate neurogenic inflammation in lungs of young rats infected with respiratory syncytial virus. Am J Physiol Lung Cell Mol Physiol. 2002;282:L1143–L1150.
  • Tripp RA, Barskey A, Goss L, et al. Substance p receptor expression on lymphocytes is associated with the immune response to respiratory syncytial virus infection. J Neuroimmunol. 2002;129:141–153.
  • Tripp RA, Dakhama A, Jones LP, et al. The g glycoprotein of respiratory syncytial virus depresses respiratory rates through the cx3c motif and substance p. J Virol. 2003;77:6580–6584.
  • Matsuse H, Hirose H, Tsuchida T, et al. Effects of respiratory syncytial virus infection on dendritic cells and cysteinyl leukotrienes in lung tissues of a murine model of asthma. Allergol Int Official J Jpn Soc Allergol. 2007;56:165–169.
  • Kott KS, Salt BH, McDonald RJ, et al. Effect of secondhand cigarette smoke, rsv bronchiolitis and parental asthma on urinary cysteinyl lte4. Pediatr Pulmonol. 2008;43:760–766.
  • Bem RA, Domachowske JB, Rosenberg HF. Animal models of human respiratory syncytial virus disease. Am J Physiol Lung Cell Mol Physiol. 2011;301:L148–L156.

•• This review explains the advantages and disadvantages of the different animal models for RSV infection.

  • U.S. Department of Health and Human Services, F.a.D.A., Center for Drug Evaluation and Research (CDER); (CBER), C.f.B.E.a.R. Guidance for industry product development under the animal rule [Internet]. 2014 [cited 2015 Nov 11]. Available from http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm399217.pdf.
  • Simoes EA, DeVincenzo JP, Boeckh M, et al. Challenges and opportunities in developing respiratory syncytial virus therapeutics. J Infect Dis. 2015;211(Suppl 1):S1–S20.
  • Sacco RE, Nonnecke BJ, Palmer MV, et al. Differential expression of cytokines in response to respiratory syncytial virus infection of calves with high or low circulating 25-hydroxyvitamin d3. PLoS One. 2012;7:e33074.
  • You D, Siefker DT, Shrestha B, et al. Building a better neonatal mouse model to understand infant respiratory syncytial virus disease. Respir Res. 2015;16:91.
  • Cavallaro JJ, Maassab HF. Adaptation of respiratory syncytial (rs) virus to brain of suckling mice. Proc Soc Exp Biol Med. 1966;121:37–41.
  • Kong X, Hellermann GR, Patton G, et al. An immunocompromised balb/c mouse model for respiratory syncytial virus infection. Virol J. 2005;2:3.
  • Sacco RE, Durbin RK, Durbin JE. Animal models of respiratory syncytial virus infection and disease. Curr Opin Virol. 2015;13:117–122.
  • Dreizin RS, Vyshnevetskaia LO, Bagdamian EE, et al. [Experimental rs virus infection of cotton rats. A viral and immunofluorescent study]. Vopr Virusol. 1971;16:670–676.
  • Boukhvalova MS, Prince GA, Blanco JC. The cotton rat model of respiratory viral infections. Biologicals: J Int Assoc Biol Standardiz. 2009;37:152–159.
  • Prince GA, Prieels JP, Slaoui M, et al. Pulmonary lesions in primary respiratory syncytial virus infection, reinfection, and vaccine-enhanced disease in the cotton rat (sigmodon hispidus). Lab Invest. 1999;79:1385–1392.
  • Buchholz UJ, Granzow H, Schuldt K, et al. Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (hrsv): effects on host range and evaluation as a live-attenuated hrsv vaccine. J Virol. 2000;74:1187–1199.
  • Elvander M, Vilcek S, Baule C, et al. Genetic and antigenic analysis of the g attachment protein of bovine respiratory syncytial virus strains. J Gen Virol. 1998;79(Pt 12):2939–2946.
  • Valarcher JF, Taylor G. Bovine respiratory syncytial virus infection. Vet Res. 2007;38:153–180.
  • Rebelatto MC, Mead C, HogenEsch H. Lymphocyte populations and adhesion molecule expression in bovine tonsils. Vet Immunol Immunopathol. 2000;73:15–29.
  • Casteleyn C, Breugelmans S, Simoens P, et al. The tonsils revisited: review of the anatomical localization and histological characteristics of the tonsils of domestic and laboratory animals. Clin Dev Immunol. 2011;2011:472460.
  • Irvin CG, Bates JH. Measuring the lung function in the mouse: the challenge of size. Respir Res. 2003;4:4.
  • Woolums AR, Anderson ML, Gunther RA, et al. Evaluation of severe disease induced by aerosol inoculation of calves with bovine respiratory syncytial virus. Am J Vet Res. 1999;60:473–480.
  • Heidema J, Lukens MV, Van Maren WW, et al. Cd8+ t cell responses in bronchoalveolar lavage fluid and peripheral blood mononuclear cells of infants with severe primary respiratory syncytial virus infections. J Immunol. 2007;179:8410–8417.
  • Gershwin LJ, Anderson ML, Wang C, et al. Assessment of ige response and cytokine gene expression in pulmonary efferent lymph collected after ovalbumin inhalation during experimental infection of calves with bovine respiratory syncytial virus. Am J Vet Res. 2011;72:134–145.
  • Ackermann MR. Lamb model of respiratory syncytial virus-associated lung disease: insights to pathogenesis and novel treatments. Ilar J. 2014;55:4–15.
  • Gershwin LJ, Schelegle ES, Gunther RA, et al. A bovine model of vaccine enhanced respiratory syncytial virus pathophysiology. Vaccine. 1998;16:1225–1236.
  • Meyerholz DK, Grubor B, Fach SJ, et al. Reduced clearance of respiratory syncytial virus infection in a preterm lamb model. Microbes Infect. 2004;6:1312–1319.
  • Meyerholz DK, Gallup JM, Lazic T, et al. Pretreatment with recombinant human vascular endothelial growth factor reduces virus replication and inflammation in a perinatal lamb model of respiratory syncytial virus infection. Viral Immunol. 2007;20:188–196.
  • Derscheid RJ, Gallup JM, Knudson CJ, et al. Effects of formalin-inactivated respiratory syncytial virus (fi-rsv) in the perinatal lamb model of rsv. PLoS One. 2013;8:e81472.
  • Blount RE Jr, Morris JA, Savage RE. Recovery of cytopathogenic agent from chimpanzees with coryza. Proc Soc Exp Biol Med. 1956;92:544–549.
  • Collins PL, Whitehead SS, Bukreyev A, et al. Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics. Adv Virus Res. 1999;54:423–451.
  • Szentiks CA, Kondgen S, Silinski S, et al. Lethal pneumonia in a captive juvenile chimpanzee (pan troglodytes) due to human-transmitted human respiratory syncytial virus (hrsv) and infection with streptococcus pneumoniae. J Med Primatol. 2009;38:236–240.
  • Crowe JE Jr, Bui PT, Siber GR, et al. Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (rsv) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when rsv antibodies are infused shortly before immunization. Vaccine. 1995;13:847–855.
  • Hancock GE, Smith JD, Heers KM. Serum neutralizing antibody titers of seropositive chimpanzees immunized with vaccines coformulated with natural fusion and attachment proteins of respiratory syncytial virus. J Infect Dis. 2000;181:1768–1771.
  • Schwarze J, O’Donnell DR, Rohwedder A, et al. Latency and persistence of respiratory syncytial virus despite t cell immunity. Am J Respir Crit Care Med. 2004;169:801–805.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.